Sign in

CIK 0001847367

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

ALUMIS INC.

Sign in to watch
Ticker
ALMS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 650-231-6625
Business address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Former names
FL2021-001, Inc.
Open-market buys, last 90 days
$10,726,255
in 1 filing
Open-market sales, last 90 days
$1,037,650
in 7 filings

Net +$9,688,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-11-02 Bradley Mark Christopher Chief Development Officer Sale −623 $6.52 $4K 47,910
2026-08-03 Bradley Mark Christopher Chief Development Officer Sale −2,572 $26.37 $68K 48,533
2026-01-26 Bradley Mark Christopher Chief Development Officer Grant or award · Stock Option (Right to Buy) +190,225 190,225
2025-07-29 Bradley Mark Christopher Chief Development Officer Grant or award +26,750 48,728
2025-07-29 Bradley Mark Christopher Chief Development Officer Grant or award · Stock Option (Right to Buy) +107,100 107,100
2025-02-18 Bradley Mark Christopher Chief Development Officer Grant or award · Stock Option (Right to Buy) +140,000 140,000
2024-07-01 Bradley Mark Christopher Chief Development Officer Returned to the company −21,978 0
2024-07-01 Bradley Mark Christopher Chief Development Officer Grant or award +21,978 21,978
2024-07-01 Bradley Mark Christopher Chief Development Officer Returned to the company −20,026 0
2024-07-01 Bradley Mark Christopher Chief Development Officer Grant or award +20,026 20,026
2024-07-01 Bradley Mark Christopher Chief Development Officer Returned to the company −20,026 0
2024-07-01 Bradley Mark Christopher Chief Development Officer Grant or award +20,026 20,026
2024-07-01 Bradley Mark Christopher Chief Development Officer Returned to the company · Stock Option (Right to Buy) −4,278 0
2024-07-01 Bradley Mark Christopher Chief Development Officer Grant or award · Stock Option (Right to Buy) +4,278 4,278
2024-07-01 Bradley Mark Christopher Chief Development Officer Returned to the company · Stock Option (Right to Buy) −130,481 0
2024-07-01 Bradley Mark Christopher Chief Development Officer Grant or award · Stock Option (Right to Buy) +130,481 130,481
2024-07-01 Bradley Mark Christopher Chief Development Officer Returned to the company · Stock Option (Right to Buy) −128,342 0
2024-07-01 Bradley Mark Christopher Chief Development Officer Grant or award · Stock Option (Right to Buy) +128,342 128,342
2024-07-01 Bradley Mark Christopher Chief Development Officer Returned to the company · Stock Option (Right to Buy) −12,834 0
2024-07-01 Bradley Mark Christopher Chief Development Officer Grant or award · Stock Option (Right to Buy) +12,834 12,834

Page 1 of 2 · 27 trades